Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP1 and amylin analogues owenhaskins Dec 19, 2025 2 min read Novo Nordisk has submitted a New Drug Application (NDA) to the FDA for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection, to be used with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition
### Best AOD-9604 Alternatives in 2026 If you have been using AOD-9604 or considering it as a **fat loss peptide**, these are the evidence-based alternatives: 1
Glucose-tolerance and insulin-sensitivity measurements changed in obese mice
Most importantly, neither agent has raised major red flags in terms of serious adverse events in the trials conducted to date
Furthermore, the paper delves into the genetic basis of these effects, revealing that GHK-Cu modulates the expression of numerous antioxidant genes
If a peptide remains in Category 2: Compounding may trigger FDA inspection findings Warning letters are possible State board scrutiny may increase Even if enforcement discretion shifts, the underlying legal framework remains intact unless formally amended
